As we all know, China is a big drug-like country, but the quality of medicines has always been mixed. With the national policy of the past two years (4+7 procurement, efficacy evaluation), the center of Chinese pharmaceutical companies began to shift from generics to innovation. medicine.
In fact, with the advancement of generic drug consistency evaluation and the gradual expansion of “4+7” quantity procurement, under the background of comprehensive price linkage, the downward trend of generic drug market prices has been inevitable, and the huge volume caused by purchasing is huge. The market volatility is constantly fermenting.
The industry generally believes that under the premise of ensuring the quality and efficacy of drugs, patients often lack the motivation to purchase high-priced drugs with common names. When the hospital does not complete the agreed purchase amount, the procurement and use of public hospitals are almost all selected varieties and original research. The chances and space left for ordinary "players" will be getting smaller and smaller.
However, there are indications that the likelihood that non-selected breeds will remain competitive in the in-hospital market will become even smaller, and that some uncompetitive generic pharmaceutical companies will eventually be eliminated.
Looking at the global pharmaceutical industry, the Chinese market is still not negligible. The domestic new drugs are speeding up, the state encourages innovation, and enterprises increase investment in research and development. The innovation and transformation of pharmaceutical companies has become one of the keys to grasping the market.
From imitation to innovation How to find a breakthrough in the transformation of pharmaceutical companies?
First, independent innovation and research and development
The difficulty in researching and developing new drugs, high risks, high investment, and long-term cycles have always been the pain of pharmaceutical companies. However, large domestic pharmaceutical companies, led by Hengrui Medicine and Zhengda Tianqing, have begun to transform and innovate, from imitation to imitation. The R&D path of independent innovation is developing steadily. The average annual R&D expenditure is more than 1 billion, and the R&D investment intensity is close to 10%.
Second, "cross-border" seeking breakthrough
In recent two years, many pharmaceutical companies have begun to enter the field of cosmetics and daily necessities, and have successively launched toothpaste, toiletries, facial masks and other products. For example, Tongrentang has launched three cosmetic series of Liyanfang, Yilian and Tongren Herbs for 5 years.
Although the technical research and development of cosmetics has advantages over the traditional medical model, the transformation of this model still needs a long period of development.
